| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb9b4a64a3785fb69a4208169f83fde7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55d3e2777fe369f61b016eb61e0c749c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_618ad8a49af5f38131ea4ba78d4e31de |
| publicationDate |
2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190136949-A |
| titleOfInvention |
Pharmaceutical composition comprising inhibitors of CD300c's expression or activation for preventing or treating of cancer |
| abstract |
The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising the inhibitor or activity inhibitor of CD300c, the inhibitor or activity inhibitor of CD300c according to the present invention is an intratumorally infiltrating lymphocyte and cytotoxic T lymphocytes in a cancer environment. It is expected that it can be effectively used as an immunotherapeutic agent for the treatment of various cancers because it can increase the number of cells, reduce the number of myeloid derived inhibitory cells, and effectively inhibit the growth and development of cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022250433-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210060355-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220155554-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022240260-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022240261-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021101244-A1 |
| priorityDate |
2018-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |